We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01872078
First Posted: June 7, 2013
Last Update Posted: October 12, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome

Condition Intervention Phase
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder Drug: AZD4901 (oral) Drug: Placebo to match AZD4901 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7 [ Time Frame: Day 7 ]
    Change-from-baseline of luteinising hormone area under the concentration-time curve from time zero to 8 hours postdose [AUC(0-8)] at Day 7


Enrollment: 67
Study Start Date: June 2013
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZD4901 20 mg once a day
AZD4901 20 mg once a day
Drug: AZD4901 (oral)
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Experimental: AZD4901 20mg twice a day
AZD4901 20mg twice a day
Drug: AZD4901 (oral)
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Experimental: AZD4901 40 mg twice a day
AZD4901 40 mg twice a day
Drug: AZD4901 (oral)
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Experimental: Placebo to match AZD4901 Drug: Placebo to match AZD4901
Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea (defined as ≤ 6 menses per year). Negative serum pregnancy test at screening. Negative urine pregnancy test before randomisation. Not be breast-feeding. Not have been pregnant within the 6 months prior to screening.

Exclusion Criteria:

Perimenopausal or reached natural menopause, defined as FSH > 10 IU/L. Menstruated within the month prior to the baseline visit. Hysterectomy or bilateral oophorectomy or both. Clinically relevant disease and abnormalities (past or present), and in particular causes of abnormal vaginal bleeding.

Withdrawals from oral contraceptives if their LH levels are below 3 IU/L when retested within 7 ± 1 days of the baseline visit.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01872078


Locations
United States, Florida
Miami Research Associates
Miami, Florida, United States
Research Site
Orlando, Florida, United States
United States, Missouri
Research Site
Springfield, Missouri, United States
Germany
Research Site
Berlin, Germany
United Kingdom
Research Site
Belfast, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Jyothis George, MD University of Oxford
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01872078     History of Changes
Other Study ID Numbers: D5320C00001
First Submitted: May 23, 2013
First Posted: June 7, 2013
Results First Submitted: July 22, 2015
Results First Posted: October 12, 2015
Last Update Posted: October 12, 2015
Last Verified: September 2015

Keywords provided by AstraZeneca:
Pharmacokinetics, Pharmacodynamics, endocrinopathies, PCOS, female, hormone, LH

Additional relevant MeSH terms:
Syndrome
Polycystic Ovary Syndrome
Endocrine System Diseases
Disease
Pathologic Processes
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders